Home Cart Sign in  
Chemical Structure| 91599-74-5 Chemical Structure| 91599-74-5

Structure of Benidipine HCl
CAS No.: 91599-74-5

Chemical Structure| 91599-74-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Benidipine HCl is a dihydropyridine calcium channel blocker for the treatment of hypertension.

Synonyms: KW-3049; Benidipine (hydrochloride); (±)-Benidipine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Benidipine HCl

CAS No. :91599-74-5
Formula : C28H32ClN3O6
M.W : 542.02
SMILES Code : O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)O[C@H]3CN(CC4=CC=CC=C4)CCC3.[H]Cl
Synonyms :
KW-3049; Benidipine (hydrochloride); (±)-Benidipine
MDL No. :MFCD06407650
InChI Key :KILKDKRQBYMKQX-MIPPOABVSA-N
Pubchem ID :656667

Safety of Benidipine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
GE1 cells 1, 10, 100, 1000, 10000 nM 12 hours Promoted GE1 cell proliferation PMC6430984
MLO-Y4 cells 0.1, 1, 10, 100, 1000, 10000 nM 24 hours Promoted MLO-Y4 cell proliferation PMC6430984
MC3T3-E1 cells 0.01, 0.10, 1.00 μM 21 days To evaluate the effect of Benidipine on matrix mineralization in MC3T3-E1 cells, results showed that Benidipine significantly promoted extracellular matrix mineralization. PMC8110464
Huh7 cells 10 μM 24 hours Benidipine HCl significantly inhibited HTNV replication in Huh7 cells PMC9465303
A549 cells 6.552 μM 24 hours Benidipine HCl significantly inhibited HTNV replication in A549 cells with an IC50 of 6.552 μM PMC9465303
Rat aortic endothelial cells 10 nM 30 minutes To investigate the effects of benidipine on LPC-induced suppression of [Ca2+]i increase in endothelial cells, results showed that benidipine inhibited LPC-induced suppression of [Ca2+]i increase PMC2710319
Vero cells 10 μM 36 hours Benidipine hydrochloride showed the strongest inhibitory effect on SFTSV infection (>90%) at the concentration of 10 μM. PMC6796935
HEK293T cells 1 μM 40 minutes To investigate the inhibitory mechanism of Benidipine on CaV1.2 channels, cryo-EM structural analysis revealed that Benidipine is located in the DIII-DIV fenestration site, and its hydrophobic sidechain provides additional interactions with the channel subunit α1, supporting its inhibitory effects on both L-type and T-type voltage-gated calcium channels PMC10981686
MC3T3-E1 cells 0.01, 0.10, 1.00 μM 48 hours To evaluate the effect of Benidipine on the proliferation of MC3T3-E1 cells, results showed that Benidipine significantly promoted cell proliferation in a dose-dependent manner. PMC8110464
MC3T3-E1 cells 0.01, 0.10, 1.00 μM 7, 10, 14 days To evaluate the effect of Benidipine on alkaline phosphatase (ALP) activity in MC3T3-E1 cells, results showed that Benidipine significantly increased ALP activity, especially at 10 and 14 days. PMC8110464
MRC5 normal human fibroblasts 10 μM Benidipine selectively promotes the death of cigarette smoke-induced senescent lung cells PMC10756105

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice SFTSV infection model Intragastric administration 15 mg/kg Twice a day for 7 days Benidipine hydrochloride and nifedipine significantly reduced viral loads in spleen and serum, and alleviated SFTSV-induced pathogenesis. PMC6796935
Sprague-Dawley rats Sprague-Dawley rats Oral 4 mg/kg Single dose, aortas were isolated 90 minutes after administration To investigate the protective effects of benidipine on LPC-induced impairment of endothelium-dependent relaxation, results showed that benidipine inhibited LPC-induced endothelial dysfunction PMC2710319
Rats Tooth extraction socket model Local injection 15 or 45 μg/kg Single injection, lasting 28 days Evaluated the effect of BD on bone and gingival healing at the extraction socket. Results showed BD significantly augmented bone volume and density, and also promoted epithelial wound healing. PMC6430984
Sprague-Dawley rats Myocardial ischemia/reperfusion model Intravenous injection 10 mg/kg Single dose, 10 minutes before reperfusion Benidipine exerts its antiapoptotic effect by inhibiting the mitochondrial-mediated apoptotic pathway (but not the death receptor-mediated pathway), reducing myocardial apoptosis. Specifically, it decreased TUNEL-positive staining (8.4±1.2% vs 15.3±1.3%), reduced caspase-3 activity (1.94±0.25 vs 3.43±0.29), and inhibited mitochondrial cytochrome c release and caspase-9 activation. Additionally, benidipine enhanced ERK1/2 activity and prolonged its activation duration but had no significant effect on p38 MAPK. PMC1575055
New Zealand white rabbits Myocardial ischemia/reperfusion model Intravenous injection 3 mg/kg or 10 mg/kg Single dose, observed for 4 hours and 45 minutes To investigate the effects of benidipine on myocardial infarct size, apoptosis, necrosis, and cardiac functional recovery in rabbits subjected to myocardial ischemia/reperfusion. Results showed that 10 mg/kg benidipine significantly reduced myocardial apoptosis (6.2 ±0.8% vs 12.2 ±1.1%), necrosis, and infarct size (20 ±2.3% vs 49 ±2.6%), and improved cardiac functional recovery. 3 mg/kg benidipine, without hemodynamic effects, still significantly reduced apoptosis but failed to reduce necrosis. PMC1572621
Wistar rats MRONJ-like lesion model Local injection 0.13 mg/kg, 1.3 mg/kg Single injection, lasting two weeks Promote healing of MRONJ-like lesions, reduce necrotic bone area, and promote new bone formation PMC9412249

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00135551 Cardiovascular Disease Phase 4 Completed - Japan ... More >> Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan, 755-8505 Less <<
NCT02646397 Chronic Kidney Disease Phase 4 Unknown December 2017 China, Shanghai ... More >> Department of Nephrology, Shanghai Changzheng Hospital Shanghai, Shanghai, China, 200003 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.22mL

1.84mL

0.92mL

18.45mL

3.69mL

1.84mL

References

[1]Choi NY, Choi H, et al. Neuroprotective effects of amlodipine besylate and benidipine hydrochloride on oxidative stress-injured neural stem cells. Brain Res. 2014 Mar 10;1551:1-12.

[2]Higo K, Karasawa A, et al. Protective effects of benidipine hydrochloride(KW-3049), a calcium antagonist, against experimental arterial calcinosis and endothelial dysfunction in rats. J Pharmacobiodyn. 1992 Mar;15(3):113-20.

[3]Li H, Zhang LK, Li SF, et al. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Cell Res. 2019;29(9):739‐753

[4]Çakir T, Yücetaş ŞC, Yazici GN, Sunar M, Arslan YK, Süleyman H. Effects of Benidipine Hydrochloride on Ischemia/Reperfusion-Induced Inflammatory and Oxidative Brain İnjury in Rats [published online ahead of print, 2019 Sep 23]. Turk Neurosurg. 2019;10.5137/1019-5149.JTN.27372-19.3

[5]Suzuki O, Yoshida T, Tani S, et al. Antioxidative effects of benidipine hydrochloride in patients with hypertension independent of antihypertensive effects. Relationship between blood pressure and oxidative stress. Arzneimittelforschung. 2004;54(9):505‐512

[6]Seino H, Miyaguchi S, Yamazaki T, Ota S, Yabe R, Suzuki S. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine. Arzneimittelforschung. 2007;57(8):526‐531

[7]Sasaki H, Kanai S, Oyama T, Miyashita Y, Yamamura S, Shirai K. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2006;13(3):149‐157

 

Historical Records

Categories